ARCHIVES

Campath Improves PFS In B-Cell CLL In Phase III Trial

This article is from The Cancer Letter archive.

Vol. 30 No. 1 | January 26, 2007

Download PDF Visit The Full Archive

Related Articles

Zelboraf Increased Overall Survival To 15.9 Months in Phase II Study

March 30, 2012

Sept. Is AMA’s Month of Women In Medicine

September 10, 1993

NCI, IARC Sponsors Workshop On EBV

February 14, 1975

Implantable Drug Delivery Device Offers Better Pain Relief

September 27, 2002

Breast Cancer Coalition Demonstrations Crucial To Obtaining Windfall

October 16, 1992

NCI Advisory Group, Other Cancer Meetings

February 28, 1986